Pfizer is looking to newer products and acquisitions to offset a declining Covid business.

Pfizer has been leaning on recently acquired products to offset a looming patent cliff.

The true narrative for Pfizer (PFE) is not its recent top line earnings beat but the escalating structural tension between ...

For the quarter ended March 2026, Pfizer (PFE) reported revenue of $14.45 billion, up 5.4% over the same period last year. EPS came in at $0.75, compared to $0.92 in the year-ago quarter. The reported ...

Pfizer (PFE) stock gained 0.5% premarket after Q1 EPS of $0.75 topped forecasts. Eliquis drove revenue strength as company ...

Revenue reached $14.45 billion, up 5% year-over-year, as oncology and other recently launched products offset steep declines ...

Pfizer is also demonstrating that its commercial portfolio can flourish beyond the historically mammoth sales of its COVID-19 ...

Pfizer's Schaeffer's Volatility Scorecard (SVS) comes in at 6 out of 100. In other words, shares have consistently realized ...

Despite the continued decline of Pfizer's COVID-19 products, shares stayed stable on Tuesday morning after the New York ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Pfizer (PFE) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important ...